Circassia’s cat allergy therapy is the first of a new class of allergy treatments – Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). In common with our other SPIREs, the treatment was developed using our ToleroMune® technology. Our cat allergy therapy is currently undergoing the final phase of clinical testing.
Cat allergy is one of the most common allergies. In Europe and the US, between 8 and 17% of the population are sensitized to the proteins in cat saliva, urine and skin flakes (dander) that are responsible for allergic reactions. These allergens are widespread in the environment and therefore difficult to avoid. Cat allergy is a perennial condition, and can reduce sufferers’ quality of life and impact social lives, preventing visits to friends and relatives who have cats.
Cat allergy treatment
Circassia’s cat allergy treatment contains seven synthetically produced peptides identified from the main allergen responsible for allergy to cats (Fel d 1). It has successfully completed a number of phase II studies, and achieved very encouraging results. These showed that a short course of treatment has the potential to greatly reduce patients’ symptoms, while also having a favorable safety profile. In long-term follow up, patients’ symptoms remained greatly improved two years after the start of the study, despite no further treatment after the initial four-dose, 12-week course. The treatment is currently in phase III testing, with the results anticipated in Q2 2016.
Pipeline status: Cat allergy